Close Menu

DiaCarta

The test is designed to detect the SARS-CoV-2 Orf1ab gene in upper respiratory specimens and sputum, according to the California-based company.

The company said it has recently expanded its manufacturing capacity to 500,000 tests per week and is planning to increase it another fourfold.

The company's in vitro diagnostic qRT-PCR test detects viral RNA and targets three genes of the SARS-CoV-2 virus: the N, Orf1ab, and E genes.

DiaCarta scientists will partner with the University of Florida Health Cancer Center to analyze blood samples from up to 500 cancer patients undergoing radiotherapy.

The deal makes Arrow the sole distributor for the DiaCarta ColoScape test in Italy, San Marino, and Vatican City.

The companies plan to commercialize MIODx's immune sequencing technology for diagnostic purposes.

The financing will support the company as it works to expand its diagnostic products for non-invasive early detection and monitoring of cancers.

The company presented new data from its validation of the PCR-based approach at a conference, citing plans to advance the kit for monitoring and early detection applications.

The test kit runs on standard qPCR platforms in under three hours, and detects 20 cancer-associated biomarkers from four oncogenes. 

The company is working with the University of Florida Health Cancer Center to validate its RadTox QuantiDNA test as a monitor of cfDNA in patient plasma.

Pages

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.